A Phase 3 Study of Reproxalap in Subjects With Allergic Conjunctivitis

Condition:   Allergic Conjunctivitis Interventions:   Drug: Reproxalap Ophthalmic Solution (0.25%);   Drug: Reproxalap Ophthalmic Solution (0.5%);   Drug: Vehicle Ophthalmic Solution Sponsor:   Aldeyra Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials